SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.87-2.3%Dec 5 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (3009)2/27/2001 7:15:17 PM
From: Michael Young   of 52153
 
>>However, by going with QTRN as the marketing partner rather than a big pharma, they have likely reduced their peak sales quite a bit. Further, it is tough to change long-established ER practice, and so early sales could be slow.>>

I must admit I'm not counting on those high revenue estimates. Seems pretty much like guesswork at this point. Although the VMAC trial data released in November has changed my outlook on the drug's potential.

I'm not worried about the QTRN deal. Any reduced sales are more than made up for by SCIO's increased take of the total pie. I have no doubt that QTRN can field a competent sales force of 150+ who can aggressively market the drug.

MIKE
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News